Recruiting
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
About this study
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Condition
- Alzheimer Disease
- Tested
- 18F-Fluselenamyl
- Sponsor
- Washington University School of Medicine
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Alzheimer Disease
- Male or Female, any race
- Age ≥ 18 years
- Healthy volunteers or volunteers with Alzheimer's disease
Exclusion 8
- Has hypersensitivity to 18F-Fluselenamyl or any of its excipients ;
- Has hypersensitivity to 11C-PIB or any of its excipients ;
- Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
- Unwilling or unable to undergo PET scans tracer injections ;
- Unwilling or unable to undergo MRI (Aim 2 and Aim 3)
- Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
- Women who are currently pregnant or breast-feeding;
- Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.
Where
1 site, 1 recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Contact
-
Jayashree Rajamanickam
314 273 6140 jayashree.r@wustl.edu
-
Kelley Jackson
Potential match only. Final eligibility is determined by the study team.